Literature DB >> 6318659

Kinetic analysis in cell culture of the reversal of antiherpes activity of nucleoside analogs by thymidine.

A Larsson, G Brännström, B Oberg.   

Abstract

The inhibition of herpes simplex virus type 1 plaque formation by acyclovir, bromovinyldeoxyuridine, 9-(3,4-dihydroxybutyl)guanine, and 9-(4-hydroxybutyl)guanine at different thymidine concentrations was analyzed in Lineweaver-Burk plots. Linear competitive patterns between thymidine and the nucleoside analogs were observed for the inhibition of herpes simplex virus type 1 plaque formation. A new constant, the reversal constant Kr, was introduced to describe the sensitivity in cell culture of an antiviral drug to the reversal of its viral activity by a metabolite (e.g., thymidine).

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6318659      PMCID： PMC185953          DOI： 10.1128/AAC.24.5.819

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  The kinetics of enzyme-catalyzed reactions with two or more substrates or products. II. Inhibition: nomenclature and theory.

Authors:  W W CLELAND
Journal:  Biochim Biophys Acta       Date:  1963-02-12

2.  Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine.

Authors:  J A Fyfe; P M Keller; P A Furman; R L Miller; G B Elion
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

3.  Antiviral activity of 5-methylthiomethyl-2'-deoxyuridine and other 5-substituted 2'-deoxyuridines.

Authors:  E De Clercq; J Descamps; C L Schmidt; M P Mertes
Journal:  Biochem Pharmacol       Date:  1979-11-15       Impact factor: 5.858

4.  Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities.

Authors:  P M Keller; J A Fyfe; L Beauchamp; C M Lubbers; P A Furman; H J Schaeffer; G B Elion
Journal:  Biochem Pharmacol       Date:  1981-11-15       Impact factor: 5.858

5.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors:  E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

6.  Comparative efficacy of antiherpes drugs in different cell lines.

Authors:  E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

7.  Antiviral action and cellular toxicity of four thymidine analogues: 5-ethyl-,5-vinyl-, 5-propyl-, and 5-allyl-2'- deoxyuridine.

Authors:  Y C Cheng; B A Domin; R A Sharma; M Bobek
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

8.  Intracellular pools of thymidine reduce the antiviral action of acyclovir.

Authors:  J Harmenberg
Journal:  Intervirology       Date:  1983       Impact factor: 1.763
  8 in total
  10 in total

1.  Mutation within the herpes simplex virus DNA polymerase gene conferring resistance to (R)-9-(3,4-dihydroxybutyl)guanine.

Authors:  H C Chiou; K M Kerns; D M Coen
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

2.  Influence of acyclovir and bucyclovir on nucleotide pools in cells infected with herpes simplex virus type 1.

Authors:  A H Karlsson; J G Harmenberg; B E Wahren
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

3.  Effects of ribonucleotide reductase inhibition on pyrimidine deoxynucleotide metabolism in acyclovir-treated cells infected with herpes simplex virus type 1.

Authors:  A Karlsson; J Harmenberg
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

4.  Efficacies of antiherpesvirus nucleosides against two strains of herpes simplex virus type 1 in Vero and human embryo lung fibroblast cells.

Authors:  T Suzutani; H Machida; T Sakuma
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

5.  Quantitative analysis of antiviral drug toxicity in proliferating cells.

Authors:  K Stenberg; J Wangenheim; B Tribukait
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

6.  Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug.

Authors:  D M Lake-Bakaar; G Abele; B Lindborg; K F Soike; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

7.  Antiherpes effects and pharmacokinetic properties of 9-(4-hydroxybutyl) guanine and the (R) and (S) enantiomers of 9-(3,4-dihydroxybutyl)guanine.

Authors:  A C Ericson; A Larsson; F Y Aoki; W A Yisak; N G Johansson; B Oberg; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection.

Authors:  S L Spruance; D J Freeman; N V Sheth
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

9.  Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.

Authors:  Eisuke Murakami; Haiying Bao; Mangala Ramesh; Tamara R McBrayer; Tony Whitaker; Holly M Micolochick Steuer; Raymond F Schinazi; Lieven J Stuyver; Aleksandr Obikhod; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

10.  Chapter 3 Antiviral drugs: general considerations.

Authors: 
Journal:  Perspect Med Virol       Date:  2008-05-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.